Clincosm LogoSign in Get a demo

EV ICD CA: ExtraVascular Implantable Cardiac Defibrillator Continued Access Study

Sponsor
Medtronic (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05049720
Collaborator
(none)
200
Enrollment
1
Arm
11.9
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

This study is designed to provide continued access to the Extravascular Implantable Cardioverter Defibrillator (EV ICD) System.

Condition or Disease Intervention/Treatment Phase
  • Device: Defibrillation using the Extravascular ICD
 N/A

Detailed Description

The study will enroll subjects who are indicated to receive an implantable defibrillator who meet all of the inclusion criteria and none of the exclusion criteria. Subjects will receive an investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system, in which a lead is placed outside of the heart and veins to deliver defibrillation therapy. Subjects will be followed every 6 months following system implantation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
ExtraVascular Implantable Cardiac Defibrillator Continued Access Study
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Jul 28, 2023
Anticipated Study Completion Date :
Jul 28, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental

Patients will be implanted with an Extravascular ICD and undergo requisite electrical testing.

Device: Defibrillation using the Extravascular ICD
VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.

Outcome Measures

Primary Outcome Measures

  1. Complications [Through study completion, an average of 18 months]

    EV ICD system and/or procedure related adverse events

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Patient has a Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines.[1]

  2. Patient is willing and able to sign and date the Informed Consent Form for their participation in the study.

  3. Patient is at least 18 years of age and meets age requirements per local law.

  4. Patient is geographically stable and willing and able to comply with the study procedures and visits for the duration of the follow-up.

Exclusion Criteria:

  1. Patient has indications for bradycardia pacing[2] or Cardiac Resynchronization Therapy (CRT)[3] (Class I, IIa, or IIb indication).

  2. Patients with an existing pacemaker, ICD, or CRT device or leads.

  3. Patients with these medical interventions are excluded from participation in the study:

  • Prior sternotomy

  • Any prior medical condition or procedure that leads to adhesions in the anterior mediastinal space (i.e., prior mediastinal instrumentation, mediastinitis)

  • Prior abdominal surgery in the epigastric region

  • Planned sternotomy

  • Prior chest radiotherapy

Or any other prior/planned medical intervention not listed that precludes their participation in the opinion of the Investigator.

  1. Patients with these medical conditions or anatomies are excluded from participation in the study:

  • Hiatal hernia that distorts mediastinal anatomy

  • Marked sternal abnormality (e.g., pectus excavatum that impedes the substernal tunneling path or procedure)

  • Decompensated heart failure

  • COPD with oxygen dependence

  • Gross hepatosplenomegaly

Or any other known medical condition or anatomy type not listed that precludes their participation in the opinion of the Investigator.

  1. Patients with a medical condition that precludes them from undergoing defibrillation testing:

  • Severe aortic stenosis

  • Current Intracardiac LA or LV thrombus

  • Severe proximal three-vessel or left main coronary artery disease without revascularization

  • Hemodynamic instability

  • Unstable angina

  • Recent stroke or transient ischemic attack (within the last 6 months)

  • Known inadequate external defibrillation

  • LVEF < 20%

  • LVEDD >70 mm

Or any other known medical condition not listed that precludes their participation in the opinion of the Investigator.

  1. Patient with any evidence of active infection or undergoing treatment for an infection.

  2. Patient is contraindicated from temporary suspension of oral/systemic anticoagulation.

  3. Patient with current implantation of neurostimulator or any other chronically implanted device that delivers current in the body.

  4. Patient meets ACC/AHA/HRS or ESC clinical guideline Class III criteria for an ICD (e.g., life expectancy of less than 12 months).

  5. Patient is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager.

  6. Patient with any exclusion criteria as required by local law (e.g., age or other).

  7. Pregnant women or breastfeeding women, or women of childbearing potential and who are not on a reliable form of birth regulation method or abstinence*

(*If required by local law, women of child-bearing potential must undergo a pregnancy test within seven days prior to EV ICD Continued Access Study procedures)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Medtronic

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Medtronic
ClinicalTrials.gov Identifier:
NCT05049720
Other Study ID Numbers:
  • MDT20054
First Posted:
Sep 20, 2021
Last Update Posted:
Jun 27, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:
Tachycardia

Study Results

No Results Posted as of Jun 27, 2022